title: Systemic sarcoidosis first manifesting in a tattoo in the setting of immune checkpoint inhibition.
abstract: The use of immune checkpoint inhibitors is revolutionising the treatment of cancer. However, their unique toxicity profile is substantially different from what has been observed with traditional chemotherapy, resulting in a novel learning curve for medical oncologists. Early recognition of these toxicities can make a substantial impact in ameliorating these side effects in the oncological and medical-surgical fields. Here, we present a case of Lofgren syndrome sarcoidosis, which first manifested in a tattoo in a patient with metastatic urothelial cancer on therapy with anti-CTLA-4 (ipilimumab) and anti-PD1 (nivolumab).
authors: The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
authors: Charissa
authors: http://orcid.org/0000-0003-4899-5898
authors: C
authors: Kim
authors: The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
authors: Jianjun
authors: J
authors: Gao
authors: The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
authors: Vickie R
authors: VR
authors: Shannon
authors: The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
authors: Arlene
authors: A
authors: Siefker-Radtke
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D017809:Fatal Outcome; D006801:Humans; D000074324:Ipilimumab; D000072281:Lymphadenopathy / Q000000981:diagnostic imaging / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D000077594:Nivolumab; D012507:Sarcoidosis / Q000139:chemically induced* / Q000276:immunology*; D013653:Tattooing; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy*
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D000074324:Ipilimumab; D000077594:Nivolumab